John Snisarenko

John Snisarenko (senior executive) discloses dealings in 2 companies, chiefly Oyster Point Pharma, Inc. and Alimera Sciences Inc. Between 4 November 2019 and 16 September 2024, the trades on record add up to 6 filings.

Purchases make up the whole of the open-market record (3 purchases, €176k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants.

In size, the median ticket on the buying side is €45k. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 18 September 2024, the filings show a transaction in Alimera Sciences Inc. The last purchase on record was published on 11 August 2020, which is 2,264 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.